Anti‐HLA‐G CAR‐T cell therapy can benefit even low or inconsistent HLA‐G expression (Jiang et al., 2018), while engineering CAR‐T cells to produce scFv targeting PD‐1 enhances their ability to kill tumours and improves therapeutic outcomes in animal models (Nakajima et al., 2019). The gene discussed is HLA-G; the disease is neoplasm.